Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Nilotinib
60
CHF
CHF 60.00
In stock
SYN-1057-M0011 mgCHF 60.00
SYN-1057-M0055 mgCHF 84.00
SYN-1057-M01010 mgCHF 120.00
SYN-1057-M05050 mgCHF 180.00
SYN-1057-M100100 mgCHF 251.00
| Product Details | |
|---|---|
| Synonyms | AMN107; Tasigna |
| Product Type | Chemical |
| Properties | |
| Formula | C28H22F3N7O |
| MW | 529.5 |
| CAS | 641571-10-0 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: Abl - PDGFR - BCR | Kinase Group: RTK, PTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | HHZIURLSWUIHRB-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Nilotinib is an orally bio-available aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor (IC(50) <30nM) with anti-neoplastic activity.
Product References
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl: E. Weisberg, et al.; Cancer Cell. 7, 129 (2005)
Related Products
